Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Defined term · Trial design and conduct

Phase 3

Confirmatory clinical development, adequately powered for a pre-specified primary endpoint in the population for which authorisation is sought.

Document identifier
CEI-GT-062
Series
Defined term
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Phase 3

§1.2Category

Trial design and conduct — Terms describing how a clinical study is constructed and run.

§1.3Related terms

  • Phase 2 — Exploratory clinical development establishing dose and preliminary efficacy. Phase 2 estimates in selected populations are systematically larger than the confirmatory…
Compound Evidence Institute · CEI-GT-062 · https://compoundevidence.com/glossary/phase-3/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.